Method of treating prostate cancer
Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
1. A method of treating prostate cancer in a human in need of such treatment comprising administering to the human a safe and effective amount of niraparib or a salt thereof, wherein the prostate cancer is antiandrogen resistant and wherein the human (a) is not BRCA deficient or (b) is carrying at least one DNA repair anomaly selected from the group consisting of FANCA, PALB2, CHEK2, BRIP1, HDAC2, and ATM.
2. The method of claim 1 , wherein the prostate cancer is castration-resistant prostate cancer.
3. The method of claim 1 , wherein the human is carrying at least one DNA repair anomaly selected from the group consisting of FANCA, PALB2, CHEK2, BRIP1, HDAC2, and ATM.
4. The method of claim 1 , wherein the human is not BRCA deficient.
5. The method of claim 1 , wherein the prostate cancer is metastatic castration-resistant prostate cancer.
6. The method of claim 1 , wherein niraparib or a salt thereof is administered in an amount of from about 30 mg niraparib/day to about 400 mg niraparib/day.
7. The method of claim 1 , wherein niraparib or a salt thereof is administered in an amount of about 300 mg niraparib/day.
8. The method of claim 7 , wherein niraparib or a salt thereof is administered orally, once daily, in 100 mg niraparib oral dosage forms.
9. A method of treating castration- and antiandrogen-resistant prostate cancer in a human comprising administering niraparib or a salt thereof in 100 mg niraparib oral dosage forms once daily to the human, wherein the human is (a) not BRCA deficient or (b) is carrying at least one DNA repair anomaly selected from the group consisting of FANCA, PALB2, CHEK2, BRIP1, HDAC2, and ATM.
10. The method of claim 9 , wherein the human is not BRCA deficient.
11. The method of claim 9 , wherein the human is carrying at least one DNA repair anomaly selected from the group consisting of FANCA, PALB2, CHEK2, BRIP1, HDAC2, and ATM.
12. The method of claim 3 , wherein niraparib or a salt thereof is administered in an amount of from about 30 mg niraparib/day to about 400 mg niraparib/day.
13. The method of claim 3 , wherein niraparib or a salt thereof is administered in an amount of about 300 mg niraparib/day.
14. The method of claim 4 , wherein niraparib or a salt thereof is administered in an amount of from about 30 mg niraparib/day to about 400 mg niraparib/day.
15. The method of claim 4 , wherein niraparib or a salt thereof is administered in an amount of about 300 mg niraparib/day.
16. The method of claim 1 , wherein the human has had at least one line of taxane-based chemotherapy.
17. The method of claim 3 , wherein the human has had at least one line of taxane-based chemotherapy.
18. The method of claim 4 , wherein the human has had at least one line of taxane-based chemotherapy.
19. The method of claim 9 , wherein the human has had at least one line of taxane-based chemotherapy.
20. The method of claim 10 , wherein the human has had at least one line of taxane-based chemotherapy.
21. The method of claim 1 , wherein the prostate cancer has been exposed to at least one line of enzalutamide-, apalutamide-, or abiraterone acetate-based chemotherapy.
22. The method of claim 3 , wherein the prostate cancer has been exposed to at least one line of enzalutamide-, apalutamide-, or abiraterone acetate-based chemotherapy.
23. The method of claim 4 , wherein the prostate cancer has been exposed to at least one line of enzalutamide-, apalutamide-, or abiraterone acetate-based chemotherapy.